Compare Crispr Therapeutics AG (CRSP) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs NetApp Inc. — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while NetApp Inc. trades at $201.36 (market cap $38.95B). The key difference: NetApp Inc. is far larger — about 7.4× Crispr Therapeutics AG's market cap, and NetApp Inc. pays a 1.05% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NTAP | |
|---|---|---|
Market Cap | $5.23B | $38.95B |
Sector | Health | Technology |
52-Week High | $76.78 | $198.72 |
52-Week Low | $44.34 | $94.11 |
Enterprise Value | $3.65B | $38.10B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
NetApp (NTAP) trades at $202.00, up 1.65% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent acquisitions like JetStream Software and DataPelago enhancing its AI infrastructure. Earnings have consistently beaten estimates, with Q1 2026 EPS of $2.43 surpassing the $2.27 forecast. Revenue grew to $6.57B in 2025, and profitability remains robust with an 18.43% net income margin.
Outlook is positive due to strategic AI investments and earnings momentum, but risks include high valuation multiples (P/E of 31.26) and competitive pressures. Analyst consensus is mixed, with 36.62% buy ratings, though the $170.73 price target suggests caution. Investors should weigh growth prospects against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
